Treatment Modification Based on Early Assessment of CML Patients

  • STATUS
    Recruiting
  • participants needed
    300
  • sponsor
    Rabin Medical Center
Updated on 8 November 2020
imatinib
tyrosine
philadelphia chromosome
dasatinib
leukemia
kinase inhibitor
nilotinib
philadelphia chromosome positive chronic myelogenous leukemia

Summary

The investigators will check the feasibility of using early molecular response for making treatment decisions. Patients diagnosed with chronic myeloid leukemia will commence imatinib treatment. After 3 months of treatment their response will be assessed. If molecular response would be less the 10% (BCR-ABL1/ABL ISI >10%)imatinib therapy will be stopped and patients will start a different TKI (as nilotinib, dasatinib). The investigators will follow on lab and clinical outcomes.

Description

Objectives

To establish a national protocol for the treatment of patients with CML. Patients will be stratified by molecular response, and treatment will be adjusted accordingly.

Secondary outcomes To compare clinical outcomes of patients at high risk (transcript level above 10%) to those at low risk (<10%) while using the early switch approach To evaluate the prognostic value of EUTOS, HASFORD, and SOKAL scores using the early switch strategy Patients Patients may be enrolled to the protocol prior to any TKI treatment or at any time point from commencement of imatinib (started at 400 mg daily) and prior to 3 months assessment, if all the necessary baseline data is available, and all other inclusion criteria are met (patients will be excluded if they received treatment with a tyrosine kinase inhibitor other than imatinib)

Inclusion criteria:

  1. Adult patients within 6 months after the diagnosis of Philadelphia chromosome-positive CML in the chronic phase
    1. who were not previously treated (with the exception of hydroyurea) for CML or
    2. who were treated with imatinib for CML for up to 3 months, and prior to 3 months assessment (patients will be excluded if they received treatment with a tyrosine kinase inhibitor other than imatinib).
  2. Age > 18 years Diagnosis of CML will be made by conventional cytogenetic (chromosome banding analysis) and/or interphase fluorescent in situ hybridization (FISH) analysis of bone marrow containing at least one Philadelphia chromosome-positive metaphase cell. If BCR-ABL1 fusion gene (Philadelphia chromosome) is not detected by conventional cytogenetic analysis, the diagnosis of CML can be confirmed based on FISH analysis or molecular analysis (demonstration of bcr-abl by polymerase chain reaction (PCR)).

Inclusion of patients with any organ dysfunction (cardiac, renal, respiratory, liver) can be done based on the decision of the treating physician.

Exclusion criteria:

Patients will be excluded if they received treatment with a tyrosine kinase inhibitor other than imatinib (i.e., nilotinib, dasatinib) before study entry. Patients may take hydroxyurea or anagrelide for up to 4 weeks prior to imatinib treatment.

Interventions Imatinib 400 mg once daily Response will be assessed after 3 months of therapy. A complete blood count to assess hematologic response and a bone marrow biopsy and/or aspirate, including cytogenetic analysis and molecular analysis for quantitative RT-PCR for BCR-ABL1/ABL will be performed.

Response assessment Assessment of response by molecular analysis of bcr-abl1 will be performed in certified and standardized laboratories (a list of certified laboratories will be distributed).

If a patients has achieved CHR and BCR-ABL1/ABL ISI <10% at 3 months then imatinib will be continued at the dose of 400 mg daily.

If a patient has achieved CHR and BCR-ABL1/ABL ISI >10% at 3 months then imatinib will be stopped and nilotinib 300 mg twice daily or dasatinib 100 mg once daily will be instituted. ECG will be done prior to any change of therapy.

Mutation analysis is recommended prior to the commencement of nilotinib or dasatinib.

Patients will continue to receive the study treatment until the disease will progress or unacceptable toxic effects will developed. In the event of disease progression or the occurrence of adverse event treatment can be stopped or changed under the discretion of the treating physician.

Outcomes Rate of CCyR at 12 months CCyR is defined as absence of Ph-positive metaphases, determined on the basis of G-banding in at least 20 cells in metaphase per bone marrow sample Overall survival Rate of major molecular response at 6, 12, 18, 24 months Cumulative rate of optimal response at 12, 18 months

PFS

Time from commencement of imatinib till meeting ELN criteria for failure, progression to AP/BC, or death from any cause

EFS

Time from commencement of imatinib till meeting ELN criteria for failure, progression to AP/BC, grade 3 to 4 adverse event, drug discontinuation (except of the change of imatinib at 3 months according to molecular response), or death from any cause

Safety

Adverse events will be classified according to the CTCAE NCI US v.3.0 Severe AE

Details
Condition Chronic myeloid leukemia
Treatment Treatment modification based on molecular response at 3 months
Clinical Study IdentifierNCT01762969
SponsorRabin Medical Center
Last Modified on8 November 2020

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 16 yrs?
Gender: Male or Female
Do you have Chronic myeloid leukemia?
\. Adult patients within 6 months after the diagnosis of Philadelphia chromosome-positive CML in the chronic phase
who were not previously treated (with the exception of hydroyurea) for CML or
who were treated with imatinib for CML for up to 3 months, and prior to 3 months assessment (patients will be excluded if they received treatment with a tyrosine kinase inhibitor other than imatinib)
Age > 18 years Diagnosis of CML will be made by conventional cytogenetic (chromosome banding analysis) and/or interphase fluorescent in situ hybridization (FISH) analysis of bone marrow containing at least one Philadelphia chromosome-positive metaphase cell. If BCR-ABL1 fusion gene (Philadelphia chromosome) is not detected by conventional cytogenetic analysis, the diagnosis of CML can be confirmed based on FISH analysis or molecular analysis (demonstration of bcr-abl by polymerase chain reaction (PCR))
Inclusion of patients with any organ dysfunction (cardiac, renal, respiratory
liver) can be done based on the decision of the treating physician

Exclusion Criteria

Patients will be excluded if they received treatment with a tyrosine kinase
inhibitor other than imatinib (i.e., nilotinib, dasatinib) before study entry
Patients may take hydroxyurea or anagrelide for up to 4 weeks prior to
imatinib treatment
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note